« | Home | »

Aarkstore Enterprise -Growth performance, strategies and SWOT analysis:The Top 10 Pharmaceutical Companies in Latin America -Aarkstore Enterprise Mar

By | July 8, 2010

Aarkstore Enterprise -Growth performance, strategies and SWOT analysis:The Top 10 Pharmaceutical Companies in Latin America -Aarkstore Enterprise Mar

The Top 10 Pharmaceutical Companies in Latin America: Growth performance, strategies and SWOT analysis
Table of Contents :
The Top 10 Pharmaceutical Companies in Latin America
Executive summary 14
Industry overview 14
Sanofi-Aventis 15
Novartis 16
Bayer 17
Pfizer 18
Schering Plough 19
EMS 20
GlaxoSmithKline (GSK) 21
Boehringer Ingelheim 22
Roche 23
J&J (Johnson & Johnson) 24
Chapter 1 Introduction 26
What is this report about? 26
Methodology 26
Chapter 2 Industry overview 30
Summary 30
Introduction 31
Latin American market: size and growth 31
Key market drivers and resistors 33
Market drivers 33
Market resistors 34
Competitive landscape 35
Competitive position of the top 10 companies 35
Comparative analysis of the top 10 companies 37
Trends in the Latin American market 39
Regulatory environment in Latin America 39
Intellectual property 39
Brazil 39
Mexico 40
Venezuela 40
Argentina 41
Rising trial registrations 41
Regulatory harmonization and collaborations 41
Compulsory licensing trends in Latin America 41
Generic drug policy 42
Prescription policies 43
Chapter 3 Sanofi-Aventis 46
Summary 46
Introduction 47
Geographic focus 47
Marketed products 49
Therapeutic focus 49
Research and development 50
Growth strategies 51
Strengthening presence in Latin America 52
Growing business in the vaccine sector 52
SWOT analysis 53
Chapter 4 Novartis 56
Summary 56
Introduction 57
Geographic focus 57
Marketed products 59
Therapeutic focus 59
Research and development 60
Growth strategies 61
Sandoz, second largest generic player globally 61
Glivec/Gleevec positioned as flagship Novartis brand 62
Breadth of prescription pharma portfolio to provide insulation against generic threats 62
Diversification, the corporate mantra at Novartis 63
SWOT analysis 63
Chapter 5 Bayer 66
Summary 66
Introduction 67
Geographic focus 67
Marketed products 69
Therapeutic focus 69
Research and development 71
Growth strategies 71
Focus in healthcare for long-term profitability 71
New products, key for success in Latin America 72
SWOT analysis 73
Chapter 6 Pfizer 76
Summary 76
Introduction 77
Geographic focus 77
Marketed products 78
Therapeutic focus 79
Research and development 80
Growth strategies 81
M&A activities to drive sales 81
Broader therapy focus 82
SWOT analysis 83
Chapter 7 Schering Plough 86
Summary 86
Introduction 87
Geographic focus 87
Marketed products 88
Therapeutic focus 89
Research and development 90
Growth strategies 91
M&A activities to increase the companies revenue generation 91
Building a more diverse prescription drug offering to protect revenues 92
SWOT analysis 93
Chapter 8 EMS 96
Summary 96
Introduction 97
Geographic focus 97
Marketed products 98
Therapeutic focus 98
Research and development 99
Growth strategies 99
SWOT analysis 100
Chapter 9 GSK (GlaxoSmithKline) 102
Summary 102
Introduction 103
Geographic focus 103
Marketed products 104
Therapeutic focus 105
Research and development 106
Growth strategies 107
Growing diversified global business 108
Development of vaccine business 108
Continued investment in biologics 109
Delivering more products of value to the market 109
Simplify the operating model to support a diverse and growing business 110
SWOT analysis 111
Chapter 10 Boehringer Ingelheim 114
Summary 114
Introduction 115
Geographic focus 115
Marketed products 116
Therapeutic focus 117
Research and development 118
Growth strategies 119
Broader therapeutic coverage to open a greater range of opportunities 119
SWOT analysis 120
Chapter 11 Roche 122
Summary 122
Introduction 123
Geographic focus 123
Marketed products 124
Therapeutic focus 125
Research and development 126
Growth strategies 127
SWOT analysis 128
Chapter 12 J&J (Johnson & Johnson) 130
Summary 130
Introduction 130
Geographic focus 131
Marketed products 132
Therapeutic focus 132
Research and development 133
Growth strategies 134
Increasing threat of generic exposure Error! Bookmark not defined.
Lifecycle management to retain patients 134
SWOT analysis 135
Chapter 13 Other major players 138
AstraZeneca 138
Introduction 138
Geographic focus 138
Marketed products 140
Therapeutic focus 140
Research and development 142
Ache Labs 142
Introduction 142
Geographic focus 143
Marketed products 143
Therapeutic focus 144
Research and development 145
Medley 146
Introduction 146
Geographic focus 147
Marketed products 148
Therapeutic focus 148
Research and development 149
Merck & Co. 150
Introduction 150
Geographic focus 150
Marketed products 152
Therapeutic focus 152
Research and development 154
Merck KGaA 154
Introduction 154
Geographic focus 155
Marketed products 156
Therapeutic focus 156
Research and development 157
Nycomed Pharma 158
Introduction 158
Geographic focus 159
Marketed products 160
Therapeutic focus 161
Research and development 162
Eli Lilly 162
Introduction 162
Geographic focus 163
Marketed products 164
Therapeutic focus 164
Research and development 165
Wyeth 166
Introduction 166
Geographic focus 167
Marketed products 167
Therapeutic focus 168
Research and development 169
Eurofarma 170
Introduction 170
Geographic focus 170
Marketed products 172
Therapeutic focus 172
Research and development 173
Teva 174
Introduction 174
Geographic focus 175
Marketed products 176
Therapeutic focus 176
Research and development 177
Glossary 178
Index 179
List of Figures
Figure 2.1: Latin American pharmaceutical market comparison by Y-o-Y growth and CAGR (2004-08) 32
Figure 2.2: Market position of the top 10 pharmaceutical companies in Latin America, 2008 33
Figure 2.3: Key market drivers and resistors of Latin American 35
Figure 2.4: Share of top 10 pharmaceutical companies in Latin American market, 2008 36
Figure 2.5: Comparative analysis of top 10 companies 38
Figure 3.6: Sanofi-Aventis’ revenue breakdown by geography in Latin America, 2007-08 48
Figure 3.7: Sanofi-Aventis’ therapeutic focus in Latin America, 2007-08 50
Figure 3.8: Sanofi-Aventis’ SWOT analysis 53
Figure 4.9: Novartis’ revenue breakdown by geography in Latin America, 2007-08 58
Figure 4.10: Novartis’ therapeutic focus in Latin America, 2007-08 60
Figure 4.11: Novartis’ SWOT analysis 63
Figure 5.12: Bayer’s revenue breakdown by geography in Latin America, 2007-08 68
Figure 5.13: Bayer’s therapeutic focus in Latin America, 2007-08 70
Figure 5.14: Bayer’s SWOT analysis 73
Figure 6.15: Pfizer’s revenue breakdown by geography in Latin America, 2007-08 78
Figure 6.16: Pfizer’s therapeutic focus in Latin America, 2007-08 80
Figure 6.17: Pfizer’s SWOT analysis 83
Figure 7.18: Schering Plough’s revenue breakdown by geography in Latin America, 2007-08 88
Figure 7.19: Schering Plough’s therapeutic focus in Latin America, 2007-08 90
Figure 7.20: Schering Plough’s SWOT analysis 93
Figure 8.21: EMS’s revenue breakdown by geography in Latin America, 2007-08 97
Figure 8.22: EMS’s therapeutic focus in Latin America, 2007-08 99
Figure 8.23: EMS’s SWOT analysis, 2007-08 100
Figure 9.24: GSK’s revenue breakdown by geography in Latin America, 2007-08 104
Figure 9.25: GSK’s therapeutic focus in Latin America, 2007-08 106
Figure 9.26: GSK’s SWOT analysis 111
Figure 10.27: Boehringer Ingelheim’s geographic focus in Latin America, 2007-08 116
Figure 10.28: Boehringer Ingelheim’s therapeutic focus in Latin America, 2007-08 118
Figure 10.29: Boehringer Ingelheim’s SWOT analysis 120
Figure 11.30: Roche’s revenue breakdown by geography in Latin America, 2007-08 12

 

For more information, please contact :
http://www.aarkstore.com/reports/The-Top-10-Pharmaceutical-Companies-in-Latin-America-Growth-performance-strategies-and-SWOT-analysis-45477.html

Topics: Latin America Analysis | No Comments »

Comments